SAN ANTONIO--(BUSINESS WIRE)--Kinetic Concepts, Inc. (NYSE: KCI) today announced its subsidiary LifeCell has been granted CE Mark approval by the Netherlands-based notified body, KEMA, for its Strattice® Reconstructive Tissue Matrix. The CE Mark allows KCI to begin marketing Strattice in all 27 European Union member (EU) states. Strattice received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in June 2007 and has been available commercially in the U.S. since February 2008.
